Patent Oppositions in respiratory drugs industry

Explore the competitive field of respiratory drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in respiratory drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the respiratory drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the respiratory drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 9, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Neutralization Of Inhibitory Pathways In LymphocytesINNATE PHARMAMay 13, 2026STRAWMAN
Methods For Treating Nasal Polyposis By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYMay 6, 2026ENGELHARD
An Improved Pharmaceutical Composition For Nasal Use, Preparation, And Use ThereofJADRAN GALENSKI LABORATORIJ DDApr 27, 2026MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT
New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)BOEHRINGER INGELHEIMApr 9, 2026BOTTI & FERRARI
New Combination Of Active Agents For The Treatment Of Progressive Fibrosing Interstitial Lung Diseases (Pf-Ild)BOEHRINGER INGELHEIMApr 2, 2026TEVA PHARMACEUTICALS
New Oral Pharmaceutical Composition And Dose Regimen For The Therapy Of Progressive Fibrosing Interstitial Lung DiseasesBOEHRINGER INGELHEIMApr 2, 2026HAMM & WITTKOPP
Combination Therapy For Inhalation AdministrationCHEMO RESEARCHFeb 27, 2026SCORPIO
Combination Therapy For Inhalation AdministrationCHEMO RESEARCHFeb 26, 2026BRAND MURRAY FULLER
Pharmaceutical Composition Containing 2-{4-[N-(5,6-Diphenylpyrazin-2-Yl)-N-Isopropylamino]Butyloxy}-N-(Methylsulfonyl)AcetamideNIPPON SHINYAKUJan 30, 2026PRZYLUSKI
Salt Of A Pyrimido[6,1-A]Isoquinolin-4-One CompoundVERONA PHARMADec 19, 2025KELTIE

To stay ahead in the competitive respiratory drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the respiratory drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 9, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor AgonistNOVARTIS11
May 22, 2019Pharmaceutical Formulations Comprising 4-{(1R)-2- [(6-{2-[(2,6-Dichlorobenzyl)Oxy] Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2- (Hydroxymethyl)PhenolGLAXO GROUP8
Nov 1, 2023Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGY8
Jan 10, 2024Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALS8
Mar 29, 2017Compositions And Methods Of Treating Pulmonary HypertensionGILEAD SCIENCES6
May 13, 2020Methods Of Administering Pirfenidone TherapyINTERMUNE6
Apr 17, 2024Combinations Of A Muscarinic Receptor Antagonist And A Beta-2 Adrenoreceptor AgonistGLAXO GROUP5
Dec 11, 2019Administration Of Gamma Hydroxybutyrate With Monocarboxylate TransportersJAZZ PHARMACEUTICALS IRELAND5
Mar 20, 2024Therapeutic And Diagnostic Methods For CancerF HOFFMANN LA ROCHE4
May 20, 2020Methods Of Administering Fluvoxamine TherapyINTERMUNE4